CBD blocks Cav3.2 T-type calcium channels independently of CB1 receptors while THC-like agonists inhibit Cav2.2 channels through CB1, revealing distinct pain-relief mechanisms.
Pain researchers, pharmacologists, and cannabinoid scientists studying analgesic mechanisms.
Two distinct mechanismsCBD blocks Cav3.2 pores directly while CB1 agonists inhibit Cav2.2 through receptor coupling
What the researchers found
CBD directly inhibits Cav3.2 channels by occluding the pore (confirmed by homology modeling), while CB1 agonist HU-210 inhibits Cav2.2 through CB1 receptors. Intrathecal CBD reduced pain in mice, and this effect was absent in Cav3.2 null mice.
Why it matters
Understanding that different cannabinoids work through different calcium channel mechanisms explains why clinical trials of cannabinoids for pain have had mixed results and could guide development of more targeted therapies.
The numbers in context
HU-210 at 1 μM inhibited Cav2.2 with CB1 but not Cav3.2. CBD at 3 μM inhibited Cav3.2 but not Cav2.2. CBD analgesic effects were absent in Cav3.2 null mice. Effects seen in both male and female mice.
How the study worked
Electrophysiology recordings from cells expressing calcium channels, homology modeling of CBD binding, and behavioral pain testing in mouse models of inflammatory and neuropathic pain including Cav3.2 null mice.
Who was studied
In vitro cell recordings and male and female mice, including Cav3.2 null mice, in inflammatory and neuropathic pain models.
What this study cannot tell us
In vitro channel recordings may not fully reflect in vivo complexity. CBD concentrations used may not match achievable clinical levels. Mouse pain models have limited translational predictiveness.
How to read the evidence
Rigorous mechanistic study combining electrophysiology, molecular modeling, and genetic knockout validation in vivo.
When this study was published
Recent mechanistic research advancing cannabinoid pharmacology.
The bigger picture
This mechanistic work resolves a key question about why different cannabinoids have different pain-relieving profiles and provides a rational basis for developing cannabinoid-based pain therapeutics targeting specific calcium channel subtypes.
Replication
Mechanistic findings validated across multiple approaches; clinical translation needs investigation.
Funding
Not specified in abstract
Conflicts of interest
Not specified in abstract
Questions still open
- Could Cav3.2-selective drugs replicate CBD analgesic effects without other cannabinoid effects?
- Do clinical CBD doses achieve sufficient concentrations to inhibit Cav3.2 channels?
Read the original research
Differential regulation of Cav 3.2 and Cav 2.2 calcium channels by CB1 receptors and cannabidiol.
British journal of pharmacology, 180(12), 1616-1633
Citation
Harding, Erika K; Souza, Ivana A; Gandini, Maria A; Gadotti, Vinícius M; Ali, Md Yousof; Huang, Sun; Antunes, Flavia T T; Trang, Tuan; Zamponi, Gerald W. (2023). Differential regulation of Cav 3.2 and Cav 2.2 calcium channels by CB1 receptors and cannabidiol.. British journal of pharmacology, 180(12), 1616-1633. https://doi.org/10.1111/bph.16035